Elkins David V 4

What Happened

• David V. Elkins, Chief Financial Officer of Bristol Myers Squibb (BMY), sold a total of 30,000 shares in open-market transactions on April 1, 2026. The sales were: 25,519 shares at an average price of $61.60 for proceeds of $1,571,970, and 4,481 shares at an average price of $62.05 for proceeds of $278,046 — total proceeds ≈ $1,850,016. These were outright sales (not purchases or option exercises).

Key Details

• Transaction date(s): April 1, 2026; Form 4 filed April 2, 2026 (timely).
• Prices reported: weighted averages of $61.60 and $62.05. Reported price ranges: $60.900–$61.895 and $61.910–$62.201 across multiple executions (report provides weighted averages; per footnotes the filer will provide per-trade details on request).
• Shares owned after transaction: not specified in the provided filing.
• Notable footnotes: sales were made pursuant to a Rule 10b5-1 trading plan adopted June 3, 2025 (F1); weighted-average/price-range details for multiple trades (F2, F3); a note referencing a recent 401(k) plan statement (F4).
• Filing timeliness: filed the next day — not indicated as late.

Context

• These were pre-arranged sales under a 10b5-1 plan, which are common for insiders to systematically sell shares and generally indicate pre-set, not opportunistic, trading. Sales do not necessarily signal a change in company outlook; retail investors often watch purchases more closely as potential bullish signals.